The deal for the privately held U.K.-based biotechnology firm will help bolster Novartis’s oncology capabilities.

This oncology biotech advancing targeted therapies reported a notable insider sale amid ongoing clinical-stage development.

Sofinnova Partners, a leading European life sciences venture capital firm, today announced that its portfolio company Myricx Bio (“Myricx”) has reached agreement to be acquired by Novartis, for up to ...

ZURICH, July 6 (Reuters) - Swiss drugmaker Novartis said on Monday it had agreed to pay up to $1.5 billion for U.K.-based ...

Preclinical realities, therapeutic momentum, and generative AI in drug discovery ...

A German company that provides products and services that accelerate drug development and manufacturing is set to acquire the ...

Germany’s Merck KGaA will buy Bio-Techne Corp. in a deal worth $11.3 billion, one of the largest acquisitions in Minnesota ...

Orca Bio has jumped into the commercial market with FDA approval for Tregzi, a first-of-its-kind engineered cell therapy for blood cancer patients requiring transplants.    | Orca Bio has jumped into ...

What were the vibes like at BIO 2026? STAT reporters take you inside the annual industry conference on the latest episode of ...